CORMEDIX INC.: share-based compensation expense
Share-based compensation expense for CORMEDIX INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CORMEDIX INC. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 13,832,000 | USD | 2026-03-05 | 10-K · 0001213900-26-023889 |
| 2024-01-01 | 2024-12-31 | 6,129,000 | USD | 2026-03-05 | 10-K · 0001213900-26-023889 |
| 2023-01-01 | 2023-12-31 | 5,493,751 | USD | 2025-03-25 | 10-K · 0001013762-25-001852 |
| 2022-01-01 | 2022-12-31 | 4,069,520 | USD | 2024-03-12 | 10-K · 0001213900-24-021585 |
| 2021-01-01 | 2021-12-31 | 5,042,606 | USD | 2023-03-30 | 10-K · 0001213900-23-024310 |
| 2020-01-01 | 2020-12-31 | 2,499,820 | USD | 2022-03-29 | 10-K · 0001213900-22-015852 |
| 2019-01-01 | 2019-12-31 | 2,439,618 | USD | 2021-03-30 | 10-K · 0001213900-21-018684 |
| 2018-01-01 | 2018-12-31 | 1,110,632 | USD | 2020-03-16 | 10-K · 0001213900-20-006521 |
| 2017-01-01 | 2017-12-31 | 1,659,137 | USD | 2019-05-29 | 10-K · 0001654954-19-006678 |
| 2016-01-01 | 2016-12-31 | 1,335,157 | USD | 2018-03-19 | 10-K · 0001654954-18-002777 |
| 2015-01-01 | 2015-12-31 | 3,225,659 | USD | 2017-03-16 | 10-K · 0001654954-17-002094 |
| 2014-01-01 | 2014-12-31 | 2,168,303 | USD | 2017-03-16 | 10-K · 0001654954-17-002094 |
| 2013-01-01 | 2013-12-31 | 1,345,136 | USD | 2015-03-12 | 10-K · 0001354488-15-001120 |
| 2012-01-01 | 2012-12-31 | 274,358 | USD | 2014-03-31 | 10-K · 0001354488-14-001544 |
| 2011-01-01 | 2011-12-31 | 692,403 | USD | 2014-03-04 | 10-K/A · 0001354488-14-000970 |
| 2010-01-01 | 2010-12-31 | 1,167,081 | USD | 2012-04-26 | 10-K/A · 0001144204-12-024107 |
Related financial histories
- CORMEDIX INC.: total assets
- CORMEDIX INC.: total liabilities
- CORMEDIX INC.: stockholders equity
- CORMEDIX INC.: cash and cash equivalents
- CORMEDIX INC.: net income or loss
- CORMEDIX INC.: operating cash flow
- CORMEDIX INC.: capital expenditure payments
- CORMEDIX INC.: revenue
- CORMEDIX INC.: financing cash flow
- CORMEDIX INC.: investing cash flow
- CORMEDIX INC.: retained earnings or deficit
- CORMEDIX INC.: basic weighted-average shares
- CORMEDIX INC.: diluted weighted-average shares
- CORMEDIX INC.: basic earnings per share
- CORMEDIX INC.: diluted earnings per share
- CORMEDIX INC.: income tax expense or benefit
- CORMEDIX INC.: net property, plant and equipment
- CORMEDIX INC.: operating income or loss
- CORMEDIX INC.: current assets
- CORMEDIX INC.: interest expense
- CORMEDIX INC.: current liabilities
- CORMEDIX INC.: current accounts payable
- CORMEDIX INC.: net current accounts receivable
- CORMEDIX INC.: operating expenses
- CORMEDIX INC.: net inventory
- CORMEDIX INC.: gross profit
- CORMEDIX INC.: cost of revenue
- CORMEDIX INC.: selling, general and administrative expense
- CORMEDIX INC.: research and development expense
Inspect the source
- Entity
- CORMEDIX INC. / CIK 0001410098
- Captured
- 2026-09-20T08:01:45.168Z
- SEC response SHA-256
b75757faacc84388fbe591a3ec2593969ffefe3c9ea86056a188a6fcb0c2f8bb
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001410098.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))